Banyu Pharmaceutical Obtains Additional Approval for NU-LOTAN Tablet.Tokyo, Japan, Apr 24, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Banyu Pharmaceutical has obtained additional approval for NU-LOTAN Tablet 25mg/ 50mg (losartan potassium lo·sar·tan potassium n. An oral drug that was the first in the angiotensin II receptor antagonist class, used to treat hypertension. losartan potassium ), its proprietary agent for treating hypertension, from the Ministry of Health, Labor and Welfare. The agent is now available for the treatment of diabetic nephropathy (DN). This approval is based on the results from the international clinical trial called RENAAL (Reduction of Endpoint in NIDDM NIDDM abbr. non-insulin-dependent diabetes mellitus NIDDM non-insulin-dependent diabetes mellitus. NIDDM Non-insulin-dependent diabetes mellitus. See Type 2 diabetes mellitus. with A-II A-II Adults and Adolescents (Catholic movie rating) Antagonist Losartan), which covered 1,513 type-2 diabetics (including 96 Japanese patients). The first agent for DN that has been approved in Japan, NU-LOTAN Tablets is an angiotensin II receptor blocker (ARB) and is currently indicated for the treatment of DN in 59 countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion